BRAIN and NERVE－神経研究の進歩74巻5号

2022年05月発行

増大特集 次の一手—神経筋疾患難治例をどのように治療するか

標準治療で改善しない膠芽腫—予後不良な要因と次の一手

著者： 成田善孝¹

所属機関： ¹国立がん研究センター中央病院脳脊髄腫瘍科

ページ範囲：P.668 - P.676

文献概要

膠芽腫の5年生存割合は15％前後である。膠芽腫の予後因子は年齢・KPS・手術摘出度・MGMTプロモーターメチル化である。予後不良要因として①高齢者に多い，②半数が治療開始時にKPS≦70，③腫瘍の急速な増大，④全摘出可能例は半数，⑤テモゾロミド／ベバシズマブ以外に治療法がないことなどが挙げられる。がんゲノムプロファイリング検査が保険適用となり，ドライバー遺伝子が同定されるようになり，BRAF/FGFRなどに対する治験も行われるようになり，今後の治療が期待される。

参考文献

1）成田善孝. 脳腫瘍の分類と疫学. 日本臨牀 79（増刊1）: 187-193, 2021

2）Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo) 57(Suppl 1): 9-102, 2017

3）日本脳腫瘍学会（編）, 日本脳神経外科学会（監修）: 脳腫瘍診療ガイドライン2019年版—①成人脳腫瘍編・②小児脳腫瘍編. 金原出版, 東京, 2019

4）沖田典子: エビデンスに基づく膠芽腫の治療と課題. Jpn J Neurosurg 27: 91-98, 2018

5）Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, et al: Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376: 1027-1037, 2017

6）Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014

7）Chinot OL, Wick W, Mason W, Henriksson R, Saran F, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014

8）Arakawa Y, Sasaki K, Mineharu Y, Uto M, Mizowaki T, et al: A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). BMC cancer 21: 1105, 2021［doi: 10.1186/s12885-021-08834-0］

9）Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, et al: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314: 2535-2543, 2015

10）Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009

11）Balana C, Vaz MA, Manuel Sepúlveda JM, Mesia C, Del Barco S, et al: A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro-oncology 22: 1851-1861, 2020

12）Hovey EJ, Field KM, Rosenthal MA, Barnes EH, Cher L, et al: Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neurooncol Pract 4: 171-181, 2017

13）Yonezawa H, Ohno M, Igaki H, Miyakita Y, Takahashi M, et al: Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment. Jpn J Clin Oncol 51: 1028-1035, 2021

14）Tsien C, Pugh S, Dicker AP, Raizer JJ, Matuszak MM, et al: Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): randomized phase II trial of concurrent bevacizumab and re-irradiation versus bevacizumab alone as treatment for recurrent glioblastoma. Neuro Oncol 21(Suppl 6): vi20, 2019［doi: org/10.1016/j.ijrobp.2019.06.539］

15）Kawauchi D, Ohno M, Honda-Kitahara M, Miyakita Y, Takahashi M, et al: The clinical characteristics and outcomes of incidentally discovered glioblastoma. J Neurooncol 156: 551-557, 2022

16）Wakabayashi T, Natsume A, Mizusawa J, Katayama H, Fukuda H, et al: JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonbeta plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol 138: 627-636, 2018

17）Rapp M, Baernreuther J, Turowski B, Steiger HJ, Sabel M, et al: Recurrence pattern analysis of primary glioblastoma. World Neurosurg 103: 733-740, 2017

18）Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, et al: Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Bio Phys 88: 793-800, 2014

19）Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, et al: The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51: 1321-1330, 2015

20）Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, et al: Influence of treatment with tumor-treating Fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol 4: 495-504, 2018

21）Aoki T, Narita Y, Mishima K, Matsutani M: Current status of palliative and terminal care for patients with primary malignant brain tumors in Japan. Neurol Med Chir (Tokyo) 60: 600-611, 2020

22）成田善孝: がんゲノムプロファイリング検査と膠芽腫の遺伝子異常. No Shinkei Geka 50: 19-28, 2022

23）臨床研究実施計画・研究概要公開システム　https://jrct.niph.go.jp/（最終閲覧日: 2022年3月22日）

24）UMIN臨床試験登録システム　https://www.umin.ac.jp/ctr/index-j.htm（最終閲覧日: 2022年3月22日）

25）大村朋子, 宮北康二, 大村鷹希, 大野 誠, 高橋雅道, 他: 膠芽腫患者の終末期医療の実際. 第38回日本脳腫瘍学会抄録集, 2019